BTIG Downgrades Aravive to Neutral From Buy - Marketscreener.com
| ALTHX Stock | EUR 0.66 0.02 2.94% |
Slightly above 62% of Theranexus' investor base is looking to short. The analysis of current outlook of investing in Theranexus SA suggests that many traders are alarmed regarding Theranexus' prospects. Theranexus' investing sentiment overview a quick insight into current market opportunities from investing in Theranexus SA. Many technical investors use Theranexus SA stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Theranexus |
BTIG Downgrades Aravive to Neutral From Buy Marketscreener.com
Read at news.google.com
 |
Theranexus Fundamental Analysis
We analyze Theranexus' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theranexus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theranexus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Z Score
Z Score Comparative Analysis
Theranexus is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Theranexus SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theranexus stock to make a market-neutral strategy. Peer analysis of Theranexus could also be used in its relative valuation, which is a method of valuing Theranexus by comparing valuation metrics with similar companies.
Peers
Theranexus Related Equities
| OSE | OSE Pharma | 0.44 | ||||
| SIGHT | Gensight Biologics | 3.45 | ||||
| POXEL | Poxel SA | 10.00 | ||||
| ALBPS | Biophytis | 33.33 |
Additional Tools for Theranexus Stock Analysis
When running Theranexus' price analysis, check to measure Theranexus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theranexus is operating at the current time. Most of Theranexus' value examination focuses on studying past and present price action to predict the probability of Theranexus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theranexus' price. Additionally, you may evaluate how the addition of Theranexus to your portfolios can decrease your overall portfolio volatility.